Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 6/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15142756 | 0.98 | LMNA (0.37) | LMNADPP4DPP8HTR1D | |
| SCHEMBL18368343 | 0.78 | POLB (0.38) | LMNADPP4DPP8HTR1DKDM4E | |
| SCHEMBL7337621 | 0.77 | NOS3 (0.41) | — | |
| SCHEMBL30000766 | 0.77 | NOS3 (0.41) | — | |
| Hydrochloric Acid SCHEMBL17442571 | 0.75 | NOS3 (0.41) | — | |
| Hydrochloric Acid SCHEMBL7823971 | 0.75 | NOS3 (0.41) | — | |
| SCHEMBL17221363 | 0.72 | MEN1 (0.37) | DPP4DPP8 | |
| SCHEMBL17221585 | 0.72 | NOS3 (0.39) | DPP4DPP8 | |
| SCHEMBL17221566 | 0.72 | POLB (0.41) | LMNADPP4KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL12499744 | 0.71 | POLB (0.40) | LMNADPP4DPP8HTR1DKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140378474-A1 | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | NOVARTIS AG (CH) | 2014-12-25 | — | — | US | disclosed |
| US-20140378474-A1 | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | NOVARTIS AG (CH) | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378474-A1 | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | LMNA 1206/4885DPP4 206/4885DPP8 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.